These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. 188Re(CO)3-dipicolylamine-alendronate: a new bisphosphonate conjugate for the radiotherapy of bone metastases. Torres Martin de Rosales R, Finucane C, Foster J, Mather SJ, Blower PJ. Bioconjug Chem; 2010 May 19; 21(5):811-5. PubMed ID: 20387897 [Abstract] [Full Text] [Related]
6. Preparation of cyclotron-produced 186Re and comparison with reactor-produced 186Re and generator-produced 188Re for the labeling of bombesin. Moustapha ME, Ehrhardt GJ, Smith CJ, Szajek LP, Eckelman WC, Jurisson SS. Nucl Med Biol; 2006 Jan 19; 33(1):81-9. PubMed ID: 16459262 [Abstract] [Full Text] [Related]
15. Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer. Liepe K, Geidel HH, Bergmann R, Haase M, Runge R, Kotzerke J. Nucl Med Commun; 2009 Sep 19; 30(9):693-9. PubMed ID: 19528873 [Abstract] [Full Text] [Related]
19. Investigations of directly labeling antibodies with rhenium-188. Winnard P, Virzi E, Fogarasi M, Rusckowski M, Hnatowich DJ. Q J Nucl Med; 1996 Jun 19; 40(2):151-60. PubMed ID: 8909100 [Abstract] [Full Text] [Related]
20. Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas. Torres LA, Coca MA, Batista JF, Casaco A, Lopez G, García I, Perera A, Peña Y, Hernández A, Sanchez Y, Romero S, Leyva R, Prats A, Fernandez R. Nucl Med Commun; 2008 Jan 19; 29(1):66-75. PubMed ID: 18049099 [Abstract] [Full Text] [Related] Page: [Next] [New Search]